SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the community debates the market's reaction to the escalating US-Iran conflict, with many anticipating a significant downturn due to surging oil prices and inflation concerns, while others expect a 'V-recovery' based on historical resilience and the belief that the geopolitical event is already priced in.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd ($INDO) is trending amidst escalating geopolitical tensions in the Middle East, with reports of attacks on Saudi oil facilities and disruptions in the Strait of Hormuz sparking expectations of surging oil prices. The community is actively discussing a potential massive short squeeze, comparing its low-float dynamics to previous parabolic runs during global conflicts and anticipating significant gains.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as escalating US-Iran conflict, including military engagements and attacks on critical oil infrastructure like the Ras Tanura refinery, fuels widespread market uncertainty. The community remains sharply divided between those predicting a major market downturn and dip-buyers expecting a rebound from geopolitical volatility.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is surging amid escalating geopolitical tensions in the Middle East, with reports of drone strikes on Saudi Arabian oil facilities and concerns over the Strait of Hormuz driving up oil prices. The community is focused on the company's low float and high short interest, anticipating a significant short squeeze within the red-hot energy sector.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The DIA ETF is trending due to rapidly escalating geopolitical tensions in the Middle East, with community sentiment sharply divided between anticipating significant market corrections and viewing the situation as a "buy the dip" opportunity, alongside fresh tariff developments and hotter inflation data contributing to broad market volatility.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

Escalating Middle East tensions are driving discussion around USO, fueled by US-Israeli strikes, Iran's retaliation, and significant shipping disruptions in the Strait of Hormuz. The community is actively debating whether these events signal a sustained crude oil rally or if the initial price spike will quickly dissipate.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending amid escalating geopolitical tensions impacting global LNG supply routes, sparking calls for a massive short squeeze and high anticipation for its upcoming earnings. The community is highlighting the company's rapid capacity expansion and strategic positioning as an undervalued leader poised for substantial growth in a tight energy market.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing a sharp sell-off, driven by broader market jitters over geopolitical events and concerns impacting the financial sector, leading to an outsized decline compared to peers. The community is actively discussing this downturn, with many advocating to "buy the dip" citing strong fundamentals and potential S&P inclusion, while others express frustration over perceived manipulation and warn of further price deterioration.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending after acquiring StereoLabs, a strategic move widely seen by the community as foundational to becoming a unified Physical AI sensing and perception company, combining high-resolution lidar with AI vision and software to accelerate its path to profitability across robotics, industrial, and smart infrastructure markets.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as investors actively position for a market downturn, driven by mounting geopolitical tensions and widespread concerns over unsustainable tech and AI sector valuations. The community is widely discussing aggressive short positions and hedging strategies against the Nasdaq 100 amidst growing uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Senseis Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893...

Small Cap Stocks To Add to Your Watchlist - February 18th

Rackspace Technology, Direxion Daily PLTR Bear 1X Shares, Spring Valley Acquisition, Direxion Daily MU Bull 2X Shares, Sensei Biotherapeutics, Inflection Point Acquisition Corp. II, and Direxion...

<ul class="summary-bullets"><li>The company also secured a private placement financing worth around $200 million.</li><li>Sensei Biotherapeutics plans to use the majority of the proceeds to advance PIKTOR.</li><li>Remaining funds will be used for the development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.</li></ul>Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.<a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> rose to its highest since May 2024 and recorded its biggest-ever intraday gains. Trading in the stock was twice halted after the opening bell, according to Nasdaq data.The acquisition adds Faeth’s lead investigational therapy, PIKTOR, an all-oral drug combination that targets tumor metabolism and blocks multiple points in the PI3K/AKT/mTOR pathway, a critical cell signaling system that regulates cell survival, growth, and division.“In the PI3K pathway, the field has repeatedly run into the same constraint. Single-node inhibitors force a tradeoff between efficacy and tolerability. PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability,” said Anand Parikh, Co-founder of Faeth Therapeutics and the new COO and director of Sensei.<h2 class="st-heading-2">$200 Million Private Placement</h2>Sensei Biotherapeutics also secured private placement financing, worth about $200 million. The company plans to use most of the capital to advance PIKTOR, including topline results from an ongoing Phase 2 trial in second-line advanced endometrial cancer and the launch of a Phase 1b study in HR+/HER2- advanced breast cancer, both anticipated by the end of 2026.Remaining funds will support general corporate initiatives and the continued development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.The private placement attracted participation from B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, and Vivo Capital, among other life sciences funds and institutional investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish,’ amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SNSE_jpg_53f7157d12.webp" alt="SNSE.jpg">One user expects the stock to “go up big” if it holds above the $25.4 to $25.5 support. It is currently trading at around $28.<stembedurl>https://stocktwits.com/brewstocks123/message/645236001</stembedurl>Another user expects the stock to climb to $44 by the end of the session.<stembedurl>https://stocktwits.com/FreyBentos/message/645238839</stembedurl>The stock has gained around 160% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rxt-stock-soars-pre-market-palantir-connection/cZR0r6BR4vX">RXT Stock Soared 275% Today – What’s The Connection&nbsp;With Palantir?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Representative image of a trending stock chart.

 SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition

Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.

Equity

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Sensei Biotherapeutics Stock Soars 230% After Faeth Deal

SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pipeline targeting cancer.read more...

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (Faeth), a clinical-stage biotechnology company developing multi-node therapies that target...

Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder James Peyer Sells 3,105 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder James Peyer sold 3,105 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average...

James Peyer Sells 5,000 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder James Peyer sold 5,000 shares of the firm's stock in a transaction on Thursday, December 4th. The shares were sold at an...

What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After Hours Jump?

Sensei Biotherapeutics surged in after-hours trading Thursday, with strong recent gains and ongoing shareholder activity drawing attention.read more...

<ul class="summary-bullets"><li>The company stated that it anticipates reducing its workforce to conserve cash as part of its strategic review.</li><li>The company said that it decided not to initiate a new clinical study of Solnerstotug in cancer patients after reviewing “future funding needs and current capital markets environment.” &nbsp;</li></ul>Sensei Biotherapeutics, Inc. (SNSE) on Thursday said that its Board of Directors has determined to discontinue development of its lead product candidate, Solnerstotug, and initiate a comprehensive review of strategic alternatives.The Board came to the decision after extensive consideration, it said. The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations, Sensei <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/30/3177470/0/en/Sensei-Biotherapeutics-Announces-Initiation-of-Strategic-Review-to-Maximize-Shareholder-Value.html">said</a>. Further, there is no assurance that the review will result in a transaction, the company added.<h2 class="st-heading-2">Workforce Reduction Plans</h2>The company stated that it anticipates reducing its workforce to conserve cash as part of its strategic review. Details of the layoffs will be announced separately, the company said.Sensei Biotherapeutics, however, plans to retain a small team of employees to assist in the strategic review process and to manage a smooth transition of developmental activities. &nbsp;The company said that it decided not to initiate a new clinical study of Solnerstotug in cancer patients after reviewing “future funding needs and current capital markets environment.” The drug had demonstrated clinical activity in previous trials.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company rallied 5% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.SNSE stock is up 5% this year and down by 10% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options

The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, Sensei said.

The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations, Sensei said.


Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$30.50
Prev Close	$30.22
Open	$29.03
Dividend Yield	0.00%
50-Day Moving Average	$13.20
Beta	0.81
Avg. Volume	103,199.30
PE Ratio	-1.43

52-Week High	$36.76
52-Week Low	$5.00
Market Capitalization	$38.47M
EPS (Annual)	-$24.01
Price to Book	1.41
Revenue Per Employee	$0.00

SNSE
Sensei Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SNSE News

SNSESensei Biotherapeutics Inc